Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.58 USD | -1.78% | -0.77% | -23.56% |
Financials (USD)
Sales 2024 * | 31.99M | Sales 2025 * | 3.01M | Capitalization | 822M |
---|---|---|---|---|---|
Net income 2024 * | -197M | Net income 2025 * | -306M | EV / Sales 2024 * | 9.19 x |
Net cash position 2024 * | 528M | Net cash position 2025 * | 356M | EV / Sales 2025 * | 155 x |
P/E ratio 2024 * |
-4.23
x | P/E ratio 2025 * |
-3.11
x | Employees | 124 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.28% |
Latest transcript on Zentalis Pharmaceuticals, Inc.
1 day | -1.78% | ||
1 week | -0.77% | ||
Current month | +4.70% | ||
1 month | -10.65% | ||
3 months | -15.23% | ||
6 months | +11.88% | ||
Current year | -23.56% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.07% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 11.58 | -1.78% | 417,548 |
24-05-20 | 11.79 | -2.32% | 430,070 |
24-05-17 | 12.07 | +0.92% | 493,174 |
24-05-16 | 11.96 | -0.13% | 370,523 |
24-05-15 | 11.98 | +2.61% | 589,889 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.56% | 822M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.99% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- ZNTL Stock